Search results
Results from the WOW.Com Content Network
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling (IL-4R, IL-13R), used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis.
16163 Ensembl ENSG00000169194 ENSMUSG00000020383 UniProt P35225 P20109 RefSeq (mRNA) NM_002188 NM_008355 RefSeq (protein) NP_002179 NP_001341920 NP_001341921 NP_001341922 NP_032381 Location (UCSC) n/a Chr 11: 53.52 – 53.53 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Interleukin 13 (IL-13) is a protein that in humans is encoded by the IL13 gene. IL-13 was first cloned in 1993 ...
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dupilumab. PubMed provides review articles from the past five years (limit to free review articles)
What links here; Upload file; Special pages; Printable version; Page information; Get shortened URL; Download QR code
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares.
Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). [5]
In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...